These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 35975917)

  • 21. Association between methadone or buprenorphine use during medically supervised opioid withdrawal and extended-release injectable naltrexone induction failure.
    Shulman M; Choo TH; Scodes J; Pavlicova M; Wai J; Haenlein P; Tofighi B; Campbell ANC; Lee JD; Rotrosen J; Nunes EV
    J Subst Abuse Treat; 2021 May; 124():108292. PubMed ID: 33771287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Buprenorphine-naloxone vs. extended-release naltrexone for opioid use disorder in individuals with and without criminal legal involvement: A secondary analysis of the X:BOT randomized controlled trial.
    Balter DR; Puglisi LB; Dziura J; Fiellin DA; Howell BA
    J Subst Use Addict Treat; 2024 Sep; 164():209438. PubMed ID: 38857827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimizing opioid use disorder treatment with naltrexone or buprenorphine.
    Rudolph KE; Díaz I; Luo SX; Rotrosen J; Nunes EV
    Drug Alcohol Depend; 2021 Nov; 228():109031. PubMed ID: 34534863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Predictive Value of Degree of Preference for Extended-Release Naltrexone for Treatment Adherence, Opioid Use, and Relapse.
    Gaulen Z; Brenna IH; Fadnes LT; Šaltytė Benth J; Solli KK; Kunoe N; Opheim A; Tanum L
    Eur Addict Res; 2022; 28(1):56-67. PubMed ID: 34569487
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of an injectable monthly extended-release buprenorphine program in a low-barrier specialty addiction medicine clinic.
    Heil J; Salzman M; Hunter K; Baston KE; Milburn C; Schmidt R; Haroz R; Ganetsky VS
    J Subst Use Addict Treat; 2024 Jan; 156():209183. PubMed ID: 37879433
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended-release naltrexone in a residential setting.
    Mannelli P; Douaihy AB; Akerman SC; Legedza A; Fratantonio J; Zavod A; Sullivan MA
    Am J Addict; 2022 Mar; 31(2):142-147. PubMed ID: 35137481
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Explaining differential effects of medication for opioid use disorder using a novel approach incorporating mediating variables.
    Rudolph KE; Díaz I; Hejazi NS; van der Laan MJ; Luo SX; Shulman M; Campbell A; Rotrosen J; Nunes EV
    Addiction; 2021 Aug; 116(8):2094-2103. PubMed ID: 33340181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone.
    Marsden J; Kelleher M; Hoare Z; Hughes D; Bisla J; Cape A; Cowden F; Day E; Dewhurst J; Evans R; Hearn A; Kelly J; Lowry N; McCusker M; Murphy C; Murray R; Myton T; Quarshie S; Scott G; Turner S; Vanderwaal R; Wareham A; Gilvarry E; Mitcheson L
    Trials; 2022 Aug; 23(1):697. PubMed ID: 35986418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial.
    Bisaga A; Mannelli P; Yu M; Nangia N; Graham CE; Tompkins DA; Kosten TR; Akerman SC; Silverman BL; Sullivan MA
    Drug Alcohol Depend; 2018 Jun; 187():171-178. PubMed ID: 29674251
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial.
    Mannelli P; Wu LT; Peindl KS; Swartz MS; Woody GE
    Drug Alcohol Depend; 2014 May; 138():83-8. PubMed ID: 24602363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV clinic-based extended-release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non-blinded, randomized non-inferiority trial.
    Korthuis PT; Cook RR; Lum PJ; Waddell EN; Tookes H; Vergara-Rodriguez P; Kunkel LE; Lucas GM; Rodriguez AE; Bielavitz S; Fanucchi LC; Hoffman KA; Bachrach K; Payne EH; Collins JA; Matthews A; Oden N; Jacobs P; Jelstrom E; Sorensen JL; McCarty D
    Addiction; 2022 Jul; 117(7):1961-1971. PubMed ID: 35129242
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Initiating Long-acting Injectable Naltrexone: Procedure for a Second Attempt After a First Attempt Fails.
    Shulman M; Hu MC; Nunes EV; Bisaga A
    J Addict Med; 2022 Sep-Oct 01; 16(5):588-591. PubMed ID: 35165228
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk of relapse to non-opioid addictive substances among opioid dependent patients treated with an opioid receptor antagonist or a partial agonist: A randomized clinical trial.
    Opheim A; Benth JŠ; Solli KK; Kloster PS; Fadnes LT; Kunøe N; Gaulen Z; Tanum L
    Contemp Clin Trials; 2023 Dec; 135():107360. PubMed ID: 37865138
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lorcaserin treatment for extended-release naltrexone induction and retention for opioid use disorder individuals: A pilot, placebo-controlled randomized trial.
    Levin FR; Mariani JJ; Pavlicova M; Choi CJ; Basaraba C; Mahony AL; Brooks DJ; Naqvi N; Bisaga A
    Drug Alcohol Depend; 2021 Feb; 219():108482. PubMed ID: 33418204
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Revisiting the X:BOT Naltrexone Clinical Trial Using a Comprehensive Survival Analysis.
    Ajazi EM; Dasgupta N; Marshall SW; Monaco J; Howard AG; Preisser JS; Schwartz TA
    J Addict Med; 2022 Jul-Aug 01; 16(4):440-446. PubMed ID: 35960214
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder.
    Lier AJ; Seval N; Vander Wyk B; Di Paola A; Springer SA
    J Subst Abuse Treat; 2022 Nov; 142():108852. PubMed ID: 35988513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Variants of opioid genes and response to treatment of opioid use disorder with buprenorphine-naloxone versus extended-release naltrexone in Caucasians.
    Randesi M; Rotrosen J; Nunes EV; Lee JD; Novo P; Levran O; Ott J; Pavlicova M; Scodes J; Kreek MJ
    Am J Drug Alcohol Abuse; 2020 Nov; 46(6):761-768. PubMed ID: 32851876
    [No Abstract]   [Full Text] [Related]  

  • 38. Co-occurring Depression and Suicidal Ideation in Opioid Use Disorder: Prevalence and Response During Treatment With Buprenorphine-Naloxone and Injection Naltrexone.
    Na PJ; Scodes J; Fishman M; Rotrosen J; Nunes EV
    J Clin Psychiatry; 2022 Apr; 83(3):. PubMed ID: 35452194
    [No Abstract]   [Full Text] [Related]  

  • 39. Risk of Relapse Among Opioid-Dependent Patients Treated With Extended-Release Naltrexone or Buprenorphine-Naloxone: A Randomized Clinical Trial.
    Opheim A; Gaulen Z; Solli KK; Latif ZE; Fadnes LT; Benth JŠ; Kunøe N; Tanum L
    Am J Addict; 2021 Sep; 30(5):453-460. PubMed ID: 34487395
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estimating the impact of stimulant use on initiation of buprenorphine and extended-release naltrexone in two clinical trials and real-world populations.
    Cook RR; Foot C; Arah OA; Humphreys K; Rudolph KE; Luo SX; Tsui JI; Levander XA; Korthuis PT
    Addict Sci Clin Pract; 2023 Feb; 18(1):11. PubMed ID: 36788634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.